Solid phase methodology on benzhydrylamine or p-methylbenzhydrylamine resin was used for the synthesis of seven analogs of amino or deamino vasopressin with non-coded amino acid, D-homoarginine, in position 8 and D- or L- O-methyl or O-ethyl tyrosine in position 2. [L-Tyr-(Me)2, D-Har8]vasopressin (I), [D-Tyr(Me)2, D-Har8]vasopressin (II), [L-Tyr(Et)2, D-Har8]vasopressin (III), [D-Tyr(Et)2, D-Har8]vasopressin (IV), [Mpr1, L-Tyr(Me)2, D-Har8]vasopressin (V), [Mpr1, D-Tyr(Me)2, D-Har8]vasopressin (VI) and [Mpr1, D-Tyr(Et)2, D-Har8]vasopressin (VII) were synthesized. All analogs have very low antidiuretic activity. Analogs containing O-methyltyrosine of D-configuration or O-ethyltyrosine of both D- and L-configuration are low pressor inhibitors. All analogs were found to be uterotonic inhibitors, the most potent one in vitro being [Mpr1, D-Tyr(Me)2, D-Har8]vasopressin (VI) with pA2 = 9.0 and [Mpr1, D-Tyr(Et)2, D-Har8]vasopressin (VII) with pA2 = 8.8.
使用苯甲基胺或p-甲基苯甲基胺树脂的固相方法合成了七种非编码氨基酸D-同半精氨酸位于位置8和D-或L- O-甲基或O-乙基酪氨酸位于位置2的氨基或去氨基加压素类似物。[L-Tyr-(Me)2, D-Har8]加压素(I),[D-Tyr(Me)2, D-Har8]加压素(II),[L-Tyr(Et)2, D-Har8]加压素(III),[D-Tyr(Et)2, D-Har8]加压素(IV),[Mpr1, L-Tyr(Me)2, D-Har8]加压素(V),[Mpr1, D-Tyr(Me)2, D-Har8]加压素(VI)和[Mpr1, D-Tyr(Et)2, D-Har8]加压素(VII)被合成。所有类似物的抗利尿活性都非常低。含有D-构型的O-甲基酪氨酸或D-和L-构型的O-乙基酪氨酸的类似物是低抑制剂。所有类似物都被发现是子宫收缩抑制剂,体外最有效的是[Mpr1, D-Tyr(Me)2, D-Har8]加压素(VI),其pA2=9.0和[Mpr1, D-Tyr(Et)2, D-Har8]加压素(VII),其pA2=8.8。